What Is WST Fair Value?
West Pharmaceutical Services (WST) fair value estimate using multiple valuation models, updated daily.
As of August 29, 2026, West Pharmaceutical Services (WST) has a composite fair value estimate of $133.01 based on four valuation models: DCF (35% weight), Graham Number (25% weight), PEG (25% weight), and DDM (15% weight). The current market price is $337.47, suggesting the stock is overvalued by 60.6%.
Data as of August 29, 2026 (today)
Composite Fair Value
Overvalued4 of 4 models$133.01
vs. current price of $337.47(-60.6%)
How Is WST Fair Value Calculated?
Four independent models estimate what WST is worth. Each uses different inputs and assumptions. The composite blends them by weight.
WST Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
35% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$161.50
-52.1%Overvalued
Inputs used
DDM (Dividend Discount Model)
15% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$34.45
-89.8%Overvalued
Inputs used
WST Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
25% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$92.53
-72.6%Overvalued
Inputs used
PEG (Price/Earnings to Growth)
25% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$152.83
-54.7%Overvalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $337.47 is 52.1% above this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $433.4M | $391.7M |
| Year 2 | $507.4M | $414.3M |
| Year 3 | $594.0M | $438.2M |
| Year 4 | $695.3M | $463.5M |
| Year 5 | $813.9M | $490.3M |
| Year 6 | $952.7M | $518.6M |
| Year 7 | $1.12B | $548.5M |
| Year 8 | $1.31B | $580.2M |
| Year 9 | $1.53B | $613.7M |
| Year 10 | $1.79B | $649.1M |
| Terminal Value | $22.45B | $8.14B |
What Are WST's Key Financial Metrics?
Earnings & Growth
Current Price
$337.47
EPS (TTM)
$7.82
Forward P/E
33.9
Profit Margin
17.0%
Cash & Balance Sheet
Free Cash Flow
277.9M
EBITDA
912.2M
Book Value
$42.47
Total Debt
316.5M
What Do Analysts Say About WST?
Low
$340.00
Average
$404.73
High
$459.00
Upside
+19.9%
WST Fair Value FAQ
What is the fair value of WST?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), WST's estimated fair value is $133.01. The stock is currently trading at $337.47, which makes it overvalued by our analysis.
How is WST's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is WST overvalued or undervalued?
Based on our analysis, WST is overvalued. The current price of $337.47 is 60.6% above our estimated fair value of $133.01.
What do Wall Street analysts say about WST?
15 analysts cover West Pharmaceutical Services with a consensus rating of "." The average price target is $404.73, ranging from $340.00 to $459.00. This implies 19.9% upside from the current price.